A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1
To access this article, please choose from the options below
The following authors have made disclosures: J.C.: research grants: Amgen, Novartis, UCB, Centocor; consulting: Roche, UCB, CORRONA, Amgen; J.A.: speakers honoraria <$2000 from Wyeth, BMS, Abbott, Centocor, Schering-Plough; A.F.: research grants: Roche, Wyeth; Consulting: Roche, Abbott, Essex, Wyeth; J.L., J.G.: Dr. Greenberg serves as Chief Scientific Officer for CORRONA and has served on Advisory Boards for BMS, Centocor, Genentech, Roche and UCB; A.Z.: research grants: Abbott, Amgen, BMS, Schering-Plough, Roche, UCB, Wyeth; T.M.: research grants: Abbott, Amgen, UCB, (VARA); consulting: UCB; N.S. research grants: Biogen Idec, Crescendo Biosciences, Amgen; M.W. research grants: Biogen Idec, Crescendo Bioscience; consulting: Biogen Idec, Crescendo Bioscience.
All other authors have no conflicts or relevant disclosures.
This work was supported by the Doris Duke Charitable Foundation. Some of the investigators receive support from the National Institutes of Health (AR053351: J.R.C.; AR047782 and AG027066: D.H.S.).
PII: S0049-0172(10)00049-1
doi:10.1016/j.semarthrit.2010.03.003
© 2010 Elsevier Inc. All rights reserved.
